A Study of EXG102-031 in Participants With wAMD
An Open-label, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Efficacy of EXG102-031 Intraocular Injection in Participants With Neovascular Age-related Macular Degeneration(wAMD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Sara Yang
- Phone Number: +86 13957164092
- Email: sarayang@exegenesisbio.com
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100000
- Not yet recruiting
- Beijing Hospital
-
Contact:
- Haijuan Zhao
-
Principal Investigator:
- Xiaobing Yu, PhD
-
Peking, Beijing, China, 100000
- Not yet recruiting
- Beijing tongren hospital,CMU
-
Contact:
- Yuyang Dai
-
Principal Investigator:
- Wenbin Wei, PhD
-
Principal Investigator:
- Haicheng She, PhD
-
Peking, Beijing, China, 100000
- Recruiting
- Peking University People's Hospital
-
Contact:
- Lijue Wang
-
Principal Investigator:
- Mingwei Zhao, PhD
-
-
Chongqing
-
Chongqing, Chongqing, China
- Not yet recruiting
- The Southwest Hospital of Amu
-
Contact:
- Linli Xie
-
Principal Investigator:
- Yong Liu, PhD
-
-
Hubei
-
Wuhai, Hubei, China
- Recruiting
- Central theater General Hospital
-
Contact:
- Airong Yu
-
Principal Investigator:
- Yanping Song, PhD
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Not yet recruiting
- Jiangsu Provinve Hospital
-
Contact:
- Yi Chai
-
Principal Investigator:
- Qinghuai Liu, PhD
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Not yet recruiting
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contact:
- Zourong Ruan
-
Principal Investigator:
- Ke Yao, PhD
-
Wenzhou, Zhejiang, China
- Not yet recruiting
- Eye Hospital,WMU
-
Contact:
- Zhishu Bao
-
Principal Investigator:
- Jia Qu, PhD
-
Principal Investigator:
- Xiaoling Liu, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥ 50 years of age;
- Diagnosis of wAMD and current active lesion in the study eye at Screening;
- An ETDRS BCVA letter scores between 73 and 9 letters in the study eye;
- Response to anti-VEGF treatment within 6 months prior to screening or at the time of screening introduction;
- The study eye must be a Intraocular lens eye(post-cataract surgery status) and be at least 1 month post IOL implantation at enrollment;
- Voluntarily agree to participate in the clinical trial, understand the trial procedures, and be capable of signing the informed consent form before screening.
Exclusion Criteria:
- Presence of any ocular disease or history of disease in the study eye other than wAMD that may affect central visual acuity and/or macular detection;
- Presence in the study eye of CNV or macular pathology pathography due to causes other than wAMD;
- The study eye has severe and irreversible retinal structural damage involving the fovea (such as retinal pigment epithelial (RPE) atrophy, retinal fibrosis, laser scars, dense hard exudation); Or other retinal damage in the target eye that, in the opinion of the investigator, may impede visual improvement after resolution of macular edema ;
- Subretinal hemorrhage accumulating the central fovea of the study eye, with an area of hemorrhage ≥ 4 optic disc diameters;
- Presence of advanced glaucoma or uncontrolled ocular hypertension in the study eye;
- Prior receipt of any ocular or systemic gene therapy agent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose escalation-Cohort 1
Genetic : EXG102-031
|
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.
EXG102-031 will be administered by subretinal injection.
|
|
Experimental: Dose escalation-Cohort 2
Genetic : EXG102-031
|
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.
EXG102-031 will be administered by subretinal injection.
|
|
Experimental: Dose escalation-Cohort 3
Genetic : EXG102-031
|
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.
EXG102-031 will be administered by subretinal injection.
|
|
Experimental: Dose escalation-Cohort 4
Genetic : EXG102-031
|
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.
EXG102-031 will be administered by subretinal injection.
|
|
Experimental: Dose escalation-Cohort 5
Genetic : EXG102-031
|
EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.
EXG102-031 will be administered by subretinal injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)
Time Frame: 24 weeks following EXG102-031 administration
|
incidence of ocular and non-ocular AEs and SAEs
|
24 weeks following EXG102-031 administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)
Time Frame: 52 weeks following EXG102-031 administration
|
incidence of ocular and non-ocular AEs and SAEs
|
52 weeks following EXG102-031 administration
|
|
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Time Frame: 52 weeks following EXG102-031 administration
|
Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score.
A higher score represents better vision.
|
52 weeks following EXG102-031 administration
|
|
Change From Baseline in CRT (Central Retinal Thickness)
Time Frame: 52 weeks following EXG102-031 administration
|
Retinal fluid status of the study eye was evaluated using spectral domain OCT (Optical Coherence Tomography).
A decrease in value indicates a decrease in fluid
|
52 weeks following EXG102-031 administration
|
|
Supplemental Injections (Annualized Rate of Supplemental Injections)
Time Frame: 52 weeks following EXG102-031 administration
|
The number of supplemental anti-VEGF injections given after EXG102-031 was administered.
|
52 weeks following EXG102-031 administration
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mingwei ZHAO, PhD, Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EXG102-031-111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.